Join us for a Virtual R&D Day with Esperion Therapeutics, featuring Key Opinion Leaders C. Michael Gibson, MS, MD (Harvard Medical Research Institutes) and Professor Peter Libby, MD (Brigham and Women’s Hospital and Harvard Medical School) who will discuss Esperion’s discovery efforts and pipeline programs, as well as it’s landmark CLEAR Outcomes trial.

Esperion research and development leadership will provide an overview of its planned scientific focus and future growth drivers, including the CLEAR Outcomes trial for bempedoic acid, oral PCSK9 inhibitor, and Next Generation ATP citrate lyase inhibition (ACLYi) platform which have the potential to benefit people suffering from cardiovascular, hepatorenal and metabolic diseases, inflammation and oncology.

A live Q&A session will follow the formal presentations.